Crisafulli Alessandra, Altavilla Domenica, Squadrito Giovanni, Romeo Adolfo, Adamo Elena B, Marini Rolando, Inferrera Maria A, Marini Herbert, Bitto Alessandra, D'Anna Rosario, Corrado Francesco, Bartolone Sebastiano, Frisina Nicola, Squadrito Francesco
Department of Biomedical Sciences, Section of Pharmacology, University of Modena and Reggio Emilia, 41100 Modena, Italy.
J Clin Endocrinol Metab. 2004 Jan;89(1):188-92. doi: 10.1210/jc.2003-030891.
We investigated the serum levels of both receptor activator of nuclear factor kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG) in postmenopausal healthy women after a 1-yr therapy with genistein, (n = 30; 54 mg/d), hormone replacement therapy (n = 30; 1 mg/d 17beta-estradiol combined with norethisterone acetate) and placebo (n = 30). By comparison with placebo, the soluble RANKL (sRANKL)/OPG ratio was lower in the genistein group (-69 +/- 7%; P < 0.01 vs. placebo 81 +/- 24%) and in hormone replacement therapy-treated women (-11 +/- 2%; P < 0.01 vs. placebo). A positive correlation (r = 0.63; P < 0.01) was found between 1-yr percentage change in sRANKL/OPG ratio and 1-yr change in urinary deoxypyridinoline, a bone resorption marker. A negative correlation was observed between 1-yr percentage change in sRANKL/OPG ratio and 1-yr change in femoral neck bone mineral density (r = -0.7; P < 0.01). Our findings suggest that the sRANKL-OPG system may mediate the beneficial effects of genistein on bone remodeling in postmenopausal women.
我们研究了绝经后健康女性在接受1年的染料木黄酮（n = 30；54毫克/天）、激素替代疗法（n = 30；1毫克/天17β-雌二醇联合醋酸炔诺酮）和安慰剂（n = 30）治疗后血清中核因子κB受体活化因子配体（RANKL）及其诱饵受体骨保护素（OPG）的水平。与安慰剂相比，染料木黄酮组的可溶性RANKL（sRANKL）/OPG比值较低（-69±7%；与安慰剂81±24%相比，P<0.01），激素替代疗法治疗的女性也是如此（-11±2%；与安慰剂相比，P<0.01）。sRANKL/OPG比值的1年百分比变化与骨吸收标志物尿脱氧吡啶啉的1年变化之间存在正相关（r = 0.63；P<0.01）。sRANKL/OPG比值的1年百分比变化与股骨颈骨密度的1年变化之间存在负相关（r = -0.7；P<0.01）。我们的研究结果表明，sRANKL-OPG系统可能介导了染料木黄酮对绝经后女性骨重塑的有益作用。
